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Abstract: The role of circulating plasma cells (CPCs) and circulating leukemic cells (CLCs) as
biomarkers for several blood cancers, such as multiple myeloma and leukemia, respectively, have
recently been reported. These markers can be attractive due to the minimally invasive nature of
their acquisition through a blood draw (i.e., liquid biopsy), negating the need for painful bone
marrow biopsies. CPCs or CLCs can be used for cellular/molecular analyses as well, such as
immunophenotyping or fluorescence in situ hybridization (FISH). FISH, which is typically carried
out on slides involving complex workflows, becomes problematic when operating on CLCs or CPCs
due to their relatively modest numbers. Here, we present a microfluidic device for characterizing
CPCs and CLCs using immunofluorescence or FISH that have been enriched from peripheral blood
using a different microfluidic device. The microfluidic possessed an array of cross-channels (2–4 µm
in depth and width) that interconnected a series of input and output fluidic channels. Placing a
cover plate over the device formed microtraps, the size of which was defined by the width and depth
of the cross-channels. This microfluidic chip allowed for automation of immunofluorescence and
FISH, requiring the use of small volumes of reagents, such as antibodies and probes, as compared to
slide-based immunophenotyping and FISH. In addition, the device could secure FISH results in <4 h
compared to 2–3 days for conventional FISH.
Keywords: microfluidics; immunophenotyping; fish; liquid biopsy; circulating leukemia cells;
circulating plasma cells

1. Introduction
Molecular diagnostics are growing immensely due in part to the Precision Medicine Initiative
(www.whitehouse.gov/precision-medicine), which seeks to match appropriate therapies to the
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molecular characteristics of a patient’s disease. Unfortunately, the majority of molecular diagnostic
tests are expensive, involve slow turnaround times from centralized laboratories, and require highly
specialized equipment with seasoned technicians to carry out the assay. In addition, acquisition of
the molecular biomarkers requires a solid tissue or bone marrow biopsy, which can be an invasive
procedure, especially for anatomically inaccessible organs. For example, bone marrow biopsies are
typically required to monitor leukemia or multiple myeloma status, which not only complicates sample
acquisition but limits the frequency of testing.
Liquid biopsies are generating a significant amount of interest in the medical community owing
to the minimally invasive nature of acquiring biomarkers and the fact that they can enable precision
decisions on managing a variety of diseases [1,2]. Liquid biopsy markers include but are not limited to
circulating tumor cells (CTCs), cell-free DNA (cfDNA), and extracellular vesicles (EVs). As an example
of the utility of liquid biopsy analysis for some blood cancers, we have shown that circulating plasma
cells (CPCs) can be used to stage patients diagnosed with multiple myeloma [3]. Circulating leukemia
cells (CLCs) can be used to determine relapse from minimum residual disease (MRD) in patients
with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) [4], all of which typically
require a highly painful and invasive bone marrow biopsy. The challenge with using CLCs or CPCs
is that their abundance in blood is lower than what is found in the bone marrow, requiring highly
sensitive assays to analyze their molecular content following enrichment to remove interfering white
and red blood cells.
A cytogenetic method called fluorescence in-situ hybridization (FISH), which was discovered in
the early 1980s [5], can be used to detect chromosomal modifications [6–8]. FISH identifies abnormalities
in chromosomes using fluorescent DNA probes that hybridize to a specific gene region. When properly
hybridized to its complementary sequence, FISH allows for the visualization of chromosomal
aberrations, such as deletions, fusions, balanced translocations, etc. [9]. For example, cytogenetic
abnormalities are found in most cases of multiple myeloma, in which IGH translocations initiate events
associated with tumorigenesis and disease progression [10]. The progression of multiple myeloma
was discovered in clinical studies where investigators found frequent chromosomal aberrations,
such as 13q14 deletions (del13q14), 1q21 gains (amp1q21), and monosomy 13 and 17p13 deletions
(del17p13) [10,11]. B-type acute lymphoblastic leukemia (B-ALL), which is a common childhood
malignancy, is prognosed by BCR/ABL [t(9;22)], MLL [t(4;1)], and TEL/AML1 [t12;21] [12] aberrations.
While FISH assays are widely used in clinical settings, the workflow requires labor-intensive
and time-consuming protocols. Conventional slide-based methods for FISH utilize workflows that
necessitate the need for highly trained professionals and relatively high volumes of costly FISH probes;
the full assay may require 2-3 days of processing. Therefore, it is critical to develop alternative methods
and platforms to undertake FISH that address the aforementioned limitations [9,13].
Microfluidic FISH assays can address many of the limitations associated with slide-based FISH,
such as providing process automation and reducing reagent requirements and processing time [9].
Even though there are microfluidic assays that have been developed over the past years for genetic
techniques, such as PCR and DNA microarrays, less effort has been devoted toward realizing the
implementation of FISH assays using microfluidic devices [14–16]. A summary of microfluidic devices
for performing FISH are summarized in Table S1 along with their operational characteristics.
The first microfluidic for FISH was developed by Sieben and coworkers in 2007 [17]. The study
demonstrated the ability to detect a FISH signal with 10-fold higher throughput and 1/10th reagent
consumption compared to slide-based FISH. Modification of the microfluidic substrate to achieve
cell adherence is a common protocol to allow for processing the cells and imaging. Therefore, in this
report, TiO2 -modified glass slides were used for cell adherence to identify FISH signals, with the PDMS
fluidic network used to introduce FISH reagents to the target cells. The PDMS was removed from
the TiO2 -modified glass slide, and imaging was undertaken using a 100× objective [18]. Liu et al. [19]
performed FISH on centromere-sized cell arrays modified with 3-aminopropyltriethoxysilane (APTES)
or polyethylene glycol (PEG)-coated glass slides with overnight hybridization. Wang et al. [20]
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introduced an APTES-coated glass slide with a PDMS microfluidic for stretching chromosomal DNA
from a single cell to perform FISH. In a recent study, a microfluidic consisting of a Pyrex-Si stack was
generated and used for FISH to provide breast cancer prognosis [21–24]. This report reduced FISH
reagent consumption by 70% and hybridization time to 2 h.
Mayer et al. [24] used a microfluidic device to investigate HER2 amplification and immunohistochemistry
of breast cancer patients. In a further extension of this study, the authors reported short incubation
microfluidic-assisted FISH [23]. The researchers were able to reduce FISH hybridization time to 15 min
for cell lines and 35 min for human tissue slides. Microfluidic channels etched into a glass slide,
called FISHing lines, allowed the processing of 10 samples on a glass slide with 0.2 µL of FISH probe.
MRD screening using the BCR/ABL fusion gene for chronic myeloid leukemia was performed by
Mughal et al. [25].
Researchers have also reported using plastics to make the microfluidic for FISH to reduce the
fabrication cost. Kwasny et al. [26] described the use of cyclic olefin copolymer (COC) devices sealed
with glass or COC cover plates that were surface modified to allow for stretching chromosomes.
Perez-Torella and coworkers reported a COC chamber, which was capable of delivering FISH reagents
to cells [27]. The chamber was modified with 2-hydroxyethyl cellulose (HEC) to allow for cell adherence
to the chamber walls. Micro-FISH devices fabricated with CO2 laser ablation in a plastic were reported,
which resulted in a 20-fold reduction in the sample volume [28].
Our group has developed a highly sensitive microfluidic for rare cell isolation. The isolated
cells were immunostained directly within the selection chip, released into a 96-well plate, and
visualized/enumerated using fluorescence microscopy. In addition, following cell selection and
release from the isolation chip, the cells could be subjected to FISH using conventional slide-based
approaches [3,4]. Unfortunately, the workflow required extensive manual handling of cells.
To address the workflow challenge, we developed a microfluidic device named “microtrap” for
both immunophenotyping and FISH analysis of biological cells enriched from clinical samples, which
we report herein. Cells isolated on the isolation chip could be transferred to the microtrap device for
immunophenotyping and/or FISH in an automated fashion with reduced processing time.
The microtrap device consisted of an array of 80,000 containment pores generated by cross-channels
(2–4 µm in width and depth) connecting a network of interleaving fluidic channels. Unique to this
device is that it was fabricated with containment pores or microtraps that arrayed single cells in a 2-D
format and within a common imaging plane. The device does not rely on modification of the surface
to retain cells; rather, it physically entraps the cells. Additionally, imaging of the cells in the microtrap
device on different z-planes demonstrated better spatial resolution of the hybridization probes to
designate the detection of a genetic abnormality. This feature cannot be achieved in Flow-FISH
analysis [29,30]. The microtrap device provided reduced processing time (18 → 3 h) and lower amounts
of FISH probes compared to slide-based processing. The microtrap device integration to a cell selection
microfluidic allowed for automated cell processing as well as minimized the amount of operator
handling of the enriched cells, simplifying the workflow and reducing cell loss.
We demonstrate the utility of the device for the processing of non-adherent cells, such as CPCs
and CLCs, with the device being able to perform immunophenotyping and FISH from liquid biopsy
markers. In addition, we demonstrate that we can affinity-enrich B-ALL CLCs from a pediatric patient
blood sample using a cell enrichment microfluidic decorated with anti-CD19 antibodies and perform
FISH and immunophenotyping on the enriched cells using the device reported herein.
2. Materials and Methods
2.1. Design and Fabrication of the Microtrap Device
The design of the microtrap device is shown in Figure 1. There are two basic renditions, with
each differing in terms of the number of microtraps the device possessed. Design 1—single bed with
7200 microtraps; and Design 2—8-bed device with 80,000 microtraps. The microtrap size could vary
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depending on the width and depth of the cross-channels and was as small as 4 µm (width) × 2 µm
(depth) to accommodate the containment of smaller cells, such as CPCs and CLCs (6–16 µm in diameter),
compared to the larger-sized CTCs [31]. The 8-bed device (shown in Figure 1A,B) consisted of a
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The optimal device design was chosen from testing 14 different designs for which we determined
the containment efficiency of CPCs and CLCs. The 14 devices with different pore widths (4, 6, and
8 µm) and different depths (2 and 4 µm) were evaluated in terms of their ability to trap CPCs and CLCs
(data not shown). The schematic in Figure 1D shows how the cells were contained at the entrance of
the microtraps and high magnification imaging of the trapped cell as shown in Figure 1E.
An SU-8 relief was used to prepare PDMS trapping devices that were bonded to glass cover plates
to allow for high resolution fluorescence imaging. Reservoirs were formed in the PDMS device using
a sharp biopsy puncture. PDMS devices and glass cover plates (No.1 coverslips with a thickness of
0.13–0.16 mm) were cleaned with IPA, then washed with water, and air dried. We used thin glass
coverslips to facilitate the use of high NA objectives to accommodate their short working distances and
high magnification necessary for FISH. PDMS devices were bonded to the glass coverslips by treating
the surfaces with O2 plasma (50 W for 1 min). After plasma treatment, slight pressure was applied
starting from one edge to the other to avoid the trapping of air bubbles. Peak tubing was sealed with
epoxy glue to the reservoirs and a syringe pump was used to provide continuous fluid flow through
the device.
2.2. Sample loading
The microtrap device was flooded with a continuous flow of 25 µL/min of PBS buffer (pH 7.4,
100 mM) followed by flowing 0.5% BSA/PBS solution through the device using a PHD2000 syringe
pump (Harvard Apparatus, Holliston, MA, USA). Forty µL/min flow rates were used to remove air
bubbles from the device. Once the device was fully wetted with the 0.5% BSA/PBS solution, cells were
introduced into the device for either immunophenotyping or FISH at a volume flow rate of 10 µL/min.
2.3. On-Chip immunostaining
For immunostaining, live cells (RPMI-8226 or SUP-B15) were loaded as described above onto
the microtrap device. After loading target cells onto the device, 2% paraformaldehyde (PFA) was
injected at 10 µL/min for 2 min and allowed to incubate for 15 min. After incubation, the device was
washed with PBS buffer for 5 min. Fixed cells were then treated with human Fc blocker (IgG1) for
15 min to block any Fc receptors on the cell surface followed by incubation with monoclonal antibodies
for 30 min. For RPMI-8226 cells, anti-CD138 FITC (MI15, 5.0 µg/mL), anti-CD56-PE (MEM-188 clone,
20 µg/mL), and anti-CD38-APC (HIT2 clone, 2.5 µg/mL) monoclonal antibodies were used. Cells were
then washed with PBS and permeabilized with 0.1% Triton X-100 for 5 min followed by counter staining
with DAPI for 2 min.
2.4. Sample Preparation for FISH
RPMI-8226 cells were cultured as a model CPC cell line for multiple myeloma and similarly, a
SUP-B15 cell line was cultured as a model CLC for B-ALL (see Supplementary Materials for more
information). Once the cells were removed from the culture media, they were washed with 1× PBS
twice. Following the wash, the cells were re-suspended in 0.075 M KCl hypotonic solution plus 100 µL
of Colcemid to swell the cells. Colcemid helps the chromosomes to stretch, thus enhancing the clarity
and the resolution of the fluorescent probes used for FISH. Cells were fixed using Carnoy’s fixative
(methanol: glacial acetic acid = 3:1 (v/v)). Carnoy’s solution is a light fixative (no crosslinking) as
opposed to 2% PFA. During fixation, Carnoy’s fixative was added dropwise to the cells and mixed with
gentle agitation. The solution was then centrifuged at 1200 rpm for 10 min. This step was repeated
3 times and the fixed cells were stored at −20 ◦ C until being used for experiments.
2.5. On-Chip FISH
Before using fixed cell samples prepared as described above, they were mixed with fresh Carnoy’s
solution, and introduced into the microtrap device at 10 µL/min. In the case of live cell samples, cells
were fixed on-chip before processing for FISH. Once the live cells were injected and contained at
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the microtraps in the device, 0.056 M KCl hypotonic solution was injected and cells were incubated
for 10 min. After KCl treatment, cells were fixed by injecting Carnoy’s fixative and incubated for
30 min, replacing the solution with fresh Carnoy’s every 10 min. Then, all of the Carnoy’s solution was
removed by washing with PBS.
Next, the chip was washed with 2X SSC for 2 min at room temperature followed by a series of
ethanol washes (70%, 85%, and 100% EtOH) injected for 1–2 min each and dried with 100% EtOH
for 5 min. After the EtOH wash, the chip was dried completely by heating and evaporating all of
the EtOH. One µL and 10 µL of 5× diluted FISH probe mix was introduced into the single and 8-bed
device, respectively, while applying light vacuum to the outlet tubing. Once the device was filled with
FISH probes, the inlet and outlet were sealed with rubber cement. The chip was heated to 75 ◦ C for
5 min and incubated in a hybridization oven (Bambino II™ Hybridization Oven) (Boekel Scientific,
Feasterville, PA, USA) for 2 h at 37 ◦ C. Afterwards, the rubber cement was removed, and the chip was
kept at 72 ◦ C (±1 ◦ C) while washing for 2 min with 0.4X SSC (pH 7.0). The temperature of this step is
critical as it will remove the remaining free probes and keep hybridized ones associated to the target
DNA to improve imaging of the FISH signal. Next, the device was washed with 2 × SSC + 0.05%,
and Tween-20 (pH 7.0) for 1 min at room temperature. Finally, the device was washed with EtOH for
5 min and dried completely before applying 2 µL of 4-diamidino-2-phenylindole (DAPI II) for nuclear
staining. After these steps, the chip could be stored at 4 ◦ C until imaging.
2.6. Imaging On-chip and Image Processing
All imaging was performed using a Keyence BZ-X710 microscope (Keyence Cooperation of
America, Itasca, IL, USA) equipped with BZ-X filters; DAPI (Ex: 360/40 nm, Em: 460/50 nm, dichroic
mirror wavelength (DMW): 400 nm), GFP (Ex: 470/40, Em: 525/50 nm, DMW: 495 nm), TRITC (Ex:
545/25 nm, Em: 605/70 nm, DMW: 565 nm), and Cy5 (Ex: 620/60 nm, Em: 700/75 nm, DMW: 660 nm).
The microscope was equipped with a Nikon objectives (Nikon Instruments, Melville, NY, USA) CFI
Plan Apo 4× (λ 4×, NA 0.20 WD 20.00 mm), 10× (λ 10×, NA 0.45 WD 4.00 mm), 20× (λ 20×, NA
0.75 WD 1.00 mm), 40× (λ 40×, NA 0.95 WD 0.21 mm), and 60× (Apo VC 60× NA 1.40 NA WD
0.13 mm) objectives. For immunophenotyping, exposure times of 50 ms for DAPI, 500 ms for FITC,
and 1500 ms for TRITC/Cy3 and Cy5/APC were used at 10×, 20×, and 40× magnification. All images
for FISH experiments were acquired in high-resolution mode. Cell nuclei were imaged with the 60×
objective using DAPI (blue) filters (200 ms) and the FISH signals were acquired using FITC/GFP (green,
1500 ms) and (Cy5/APC)/Cy3 (red, 2500/3000 ms) channels. Due to the cell’s 3-D profile while they were
contained at the microtrap inlets, it was necessary to do imaging across the z-axis. For the imaging of
slides, we used ∆z = 2 µm for 5 different planes while for on-chip FISH imaging, cells were imaged at
10 different planes along the z-axis with ∆z = 1 µm. All images were processed using BZ-X Analyzer
(Keyence Cooperation) and FIJI software (NIH) [33].
2.7. Patient Sample Processing for FISH
CLCs from B-ALL patients were captured using the CTC isolation device described in our
earlier publications (see Supplementary Materials for more information), which was also used for
acute myeloid leukemia (AML) and multiple myeloma work [3,4]. Healthy donor blood sample
was obtained from the University of Kansas Medical Center (KUMC) IRB-approved Biospecimen
Repository Core Facility. Blood samples from a patient diagnosed with B-ALL was collected according
to an approved Children’s Mercy Hospital Institutional Review Board procedure. Written informed
consent was obtained from the patient included in the study before enrollment. Peripheral blood
samples (5 mL) were drawn by venipuncture into Vacuette® K3EDTA (Greiner Bio-one, Monroe, NC,
USA) tubes. Following affinity enrichment using the microfluidic enrichment chip, cells were released
from the capture device’s surface using USER enzyme that cleaved a single-stranded bifunctional linker
containing a uracil residue [34]. The released cells were collected into a microfuge tube and centrifuged
to prepare for immunophenotyping or FISH. For FISH, once the cells were spun down, supernatant
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was removed and pre-heated (37 ◦ C) in 0.056 M KCl and incubated for 10 min. The mixture was
centrifuged again and after removing the supernatant, ice-cold Carnoy’s fixative (if fixation was done
before introduction to the microtrap device) was added to the cells and centrifuged again. This step was
repeated 3 more times and cells were stored in Carnoy’s fixative at 20 ◦ C until further use. CLCs were
spun down and resuspended in fresh Carnoy’s solution before use. These samples were infused into
the microtrap device and processed according to the on-chip FISH procedure as described above.
3. Results
3.1. Microtrap Device for Immunophenotyping and Cytogenetic Analysis
The large number of traps in the microtrap device needed to be contained for analysis of CLCs’
and CPCs’ affinity selected from a blood sample (see Table 1). Contrary to CTCs, which use, for
example, EpCAM as the enrichment antigen, the number of non-diseased cells selected by antibodies
targeting leukemic associated and multiple myeloma antigens is high because non-diseased cells can
also express the enrichment antigen (i.e., CD19, CD34, CD117, CD33, or CD138). Following CLC or
CPC affinity selection and release from the selection chips [3], cells were trapped without surface
modifications at containment pores of the microtrap device, which were arranged in a 2-D format to
make it easier for imaging single cells. This simplified imaging was compared to cells stochastically
arranged on glass slides or wells possessing the appropriate surface chemistry. In addition, we will
show that we can interface the microtrap device for immunophenotyping and FISH of CLCs and CPCs
to a device used for their enrichment from the blood of patients.
Table 1. Number of CLCs and CPCs compared to CTCs detected in cancer patients.
Cancer Cells
(Antigen Used for Selection)

Target Cells
(mL−1 )

Non-Aberrant Cells
(mL−1 )

Cell Diameter
(µm)

Reference

CLCs
(AML, CD33, CD34, CD117)

11–2684

10–2450

11–16

[4]

CLCs (B-ALL, CD19)

40–840

400–2050

6–12

this work

CPCs (CD138)

10–5900

43–1875

12–16

[3]

CTCs in epithelial tumors
(EpCAM)

1–800

3–10

10–23

[35]

Note: The references used here were taken from a single type of cell selection chip (sinusoidal device) so that
comparisons could be made as to the numbers of the CLCs, CPCs, and CTCs secured from liquid biopsies.

Considering the size of the CLCs and CPCs with an average diameter of 6–16 µm, we used
4 × 2 µm2 microtraps to maximize the containment efficiency of CLCs and CPCs. Table 1 shows the
number of CLCs for both AML and B-ALL as well as CPCs enriched using the appropriate marker(s).
The numbers of CTCs enriched from different epithelial cancers (i.e., pancreatic, breast, prostate,
colorectal, and ovarian) is shown as well in Table 1. Not only are the number of aberrant cells enriched
higher for the leukemia and multiple myeloma diseases compared to epithelial cancers, but the number
of non-diseased cells enriched is higher as well compared to epithelial cancers due to the fact that
non-diseased blood cells can carry the same antigens as CLCs and CPCs, whereas for CTCs the blood
cells do not express EpCAM. Due to the higher number of cells anticipated for the leukemic and
multiple myeloma diseases, we had to build devices with high numbers of microtraps.
3.2. Microfluidic Containment Device Operation
The microtrap device (both single and 8-bed devices) used two independent networks of
interleaving channels that were interconnected using smaller cross-channels positioned orthogonally
to the interleaving channels. The cross-channel, when sealed with a cover plate, generated a pore
structure whose dimensions were determined by the size of the cross-channels (Figure 2A) and allowed
fluid flow between the input and output interleaving channels. During operation, CPCs/CLCs are

Cells 2019, 8, x FOR PEER REVIEW
Cells 2020, 9, 519

8 of 25
8 of 25

allowed fluid flow between the input and output interleaving channels. During operation,
CPCs/CLCs are released from the isolation chip and directed to the microtrap device, where they
become
trapped with
the efficiency
trapping
dependent
on thethey
sizebecome
of the microtrap
releasedphysically
from the isolation
chip and
directed toofthe
microtrap
device, where
physically
with
respect
tothe
theefficiency
cell of interest.
Trapped
cells could
be immunophenotyped
orrespect
subjected
to
trapped
with
of trapping
dependent
onthen
the size
of the microtrap with
to the
FISH
followed
by
imaging
with
a
fluorescence
microscope
to
read
out
the
appropriate
signals.
cell of interest. Trapped cells could then be immunophenotyped or subjected to FISH followed by
Microtrap
bedsawere
connected
in parallel to
to read
provide
numbers
of equally
accessible
imaging with
fluorescence
microscope
out sufficient
the appropriate
signals.
Microtrap
bedspores
were
toconnected
retain a large
number
of cells (see
Table numbers
1). If the eight
beds accessible
were connected
inretain
series,aalarge
majority,
if
in parallel
to provide
sufficient
of equally
pores to
number
not
all,
of
the
cells
would
be
retained
within
the
first
bed,
generating
cell
pileup
and
crowding,
thus
of cells (see Table 1). If the eight beds were connected in series, a majority, if not all, of the cells would
making
imaging
difficult.
Conversely,
placing
beds and
in parallel
(see thus
Figure
1A) allowed
to
be retained
within
the first
bed, generating
cellthe
pileup
crowding,
making
imagingaccess
difficult.
all
beds
from
a
common
input,
and
thus,
dispersed
the
cells
with
equal
probability
at
the
80,000
Conversely, placing the beds in parallel (see Figure 1A) allowed access to all beds from a common
containment
pores
associated
8-bed
device.
input, and thus,
dispersed
thewith
cellsthe
with
equal
probability at the 80,000 containment pores associated
with the 8-bed device.

Figure2.2.Simulations
Simulationsofofthe
themicrotrap
microtrapdevice.
device.(A)
(A)2-D
2-DCAD
CADdesign
designofofthe
themicrotrap
microtrapdevice
deviceused
usedfor
for
Figure
COMSOL
simulations
showing
the
interleaving
network
for
the
flow
of
fluid,
and
the
cross-channels,
which
COMSOL simulations showing the interleaving network for the flow of fluid, and the cross-channels,
produce
the microtraps
when awhen
coveraplate
is plate
sealedisto
the device.
magnified
image ofimage
the microtrap
which
produce
the microtraps
cover
sealed
to the The
device.
The magnified
of the
area
is
shown
on
the
right
with
a
single
interleaving
output
channel
(red)
and
two
interleaving
microtrap area is shown on the right with a single interleaving output channel (red) and input
two
channels (gray).
The simulated
linear
velocitylinear
throughout
the microtrap
chip. The
simulation
interleaving
input(B)
channels
(gray). (B)
Thefluid
simulated
fluid velocity
throughout
the microtrap
shows
three
sections shows
of the device:
(i) inputofsection;
(ii) middle
section;
and(ii)
(iii)middle
outlet section.
was
chip.
The
simulation
three sections
the device:
(i) input
section;
section; Flow
and (iii)
simulated
across
thewas
interleaving
channels and
the cross-channels.
box
outlet
section.
Flow
simulatedinput/output
across the interleaving
input/output
channels The
and dashed
the crossshown
here
is
the
region
of
the
device
that
was
simulated
in
Figure
S3
(see
Supplementary
Materials).
channels. The dashed box shown here is the region of the device that was simulated in Figure S3 (see
(C) Bar graph representing
theBar
mean
velocities
expressed
in m/s
observed
for the cross-channels
Supplementary
Materials). (C)
graph
representing
the mean
velocities
expressed
in m/s observedat
different sections of the device and at a 10 µL/min volume flow rate. The sections labeled here
for the cross-channels at different sections of the device and at a 10 µL/min volume flow rate. The
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Even though earlier studies from our group showed that live cells with a cell diameter of ~16 µm
(CTCs) were successfully contained by microtraps with dimensions of 8 × 4 µm2 [31], the current study
required containment of smaller cells and cell numbers that were higher (see Table 1). RPMI-8226 cells
(multiple myeloma model) have a size range of 6–16 µm with an average diameter of ~13 µm whereas
SUP-B15 cells (B-ALL model cell line) have an average size of ~10 µm with a size range of 8–12 µm.
Thus, when devices with microtraps of 8 × 4 µm2 (width × depth) were used, we observed that the
containment efficiency was <50% (data not shown). However, devices with microtraps of 4 × 2 µm2
produced a containment efficiency >90% for these cells (Figures S1 and S3B).
3.3. Device Design and COMSOL Simulations
Finite element analysis (COMSOL) was performed on the microtrap device to deduce the projected
linear velocity through the fluidic network and the corresponding shear rates to help determine the
containment efficiency of the microfluidic device to physically trap live cells without damaging them.
Laminar flow was validated across the entire device for the following flow rates: 1, 3, 5, and 10 µL/min
with an aqueous fluid (Figure S3). The rationale behind choosing these flow rates was to test the
optimal flow rate for effective containment of live cells without damage but having sufficient pressure
to fill the device without generating air bubbles. The cells used for our studies were human cancer cell
lines having a diffusion coefficient of 5 × 10−14 m2 /s [36].
The flow within the microtrap device was driven hydrodynamically, hence, a parabolic flow
profile existed with higher velocity in the center of each individual channel as compared to the channel
walls (no-slip condition; see Figure 2B) [37]. Figure 2A shows a CAD drawing of the device with
4-µm-wide microtraps and a depth of 2 µm. This device was found to provide 90% containment
efficiency for unfixed RPMI-8226 cells as shown in Figure S3A. For larger epithelial cells (i.e., SKBR3),
the containment efficiency was 96%. Cells were evenly distributed throughout the microtrap device
as well (Figure 3; Figure 4). In the experiments evaluating trapping efficiency, the cells were DAPI
stained and counted using a microscope to verify the number of cells captured. Cells that were not
retained were collected at the outlet of the microtrap device into a flat-bottomed plate and enumerated
and inspected for damage. The containment efficiency was determined from the ratio of cells in the
microtrap to the total number of cells introduced (i.e., cells trapped and cells passing through the
microtrap device).
The average velocity at the inlet and outlet interleaving channels toward the input end of the
device was 2.5 m/s and in the interleaving channels in the center of the device it was 1.5 m/s at a
volumetric flow rate of 10 µL/min. Even at these relatively high velocities, the flow was still laminar
(see Figure S3B,C). Accounting for differences in the velocity between the interleaving and cross
channels, the average velocity was calculated for the cross-channels at different sections of the device
at a 10 µL/min volume flow rate and is plotted in Figure 2C.
The average linear velocity in the cross-channels was 0.02 m/s at the 10 µL/min volumetric flow
rate. To measure the pressure drop across the device, the relative pressure at the outlet was defined in
absolute terms (pA = p + pref , where pA is the absolute pressure, p is the relative pressure, and pref is the
reference pressure, which was set to 1 atm (101 kPa) [3]. A gradual drop in pressure across the length
of the device was noted, with this drop being ~14 kPa (16 and 2 kPa at the inlet and outlet, respectively,
at 10 µL/min). The calculated shear rates at different volumetric flow rates were used to determine
the shear stress in the microtrap device [38]. According to Newton’s law, shear stress is the shear rate
times the viscosity:
Shear stress (dynes/(cm2 )) = Shear rate (1/s) × T,
(1)
where T is the dynamic viscosity (T for water is 8.90 × 10−3 dynes*s/cm2 at 25 ◦ C).
We calculated the average shear stress on the cells experienced in the microtrap device through
the entire device at different flow rates. At a flowrate of 1 µL/min, the shear rate calculated was
6042 s−1 , which corresponds to a shear stress of 54 dynes/cm2 and is 10 times higher at 10 µL/min
(Table 2). Moreover, higher shear rates were observed in the inlet and outlet of the device, where

Table 2. Average shear rate and calculated shear stress on cells at each microtrap for the flow rates
listed.

Flow Rate (µL/min)
Shear Rate (1/s)
Shear Stress (dynes/cm2)
1
6042
53.8
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3
18,206
162.0
5
30,454
271.0
cells have potentially the highest probability of being damaged when flowing near the wall of the
10
63,750
567.4
device as opposed to the center of the channel or the center area of the device where lower shear
stress is observed (Figure 2D,E). Shear rate distributions across a section of the device can be found in
The shear stress experienced by cells in physiological conditions as they travel through
Figure S3D,E.
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Figure 3. On-chip immunophenotyping of RPMI-8226 cells. (A) DAPI-labeled RPMI-8226 cell nucleus
aligned at the entrance of the microtraps formed by the cross-channels and the cover plate assembled
to the device. (B) CD138 expression of the RPMI-8226 cells and (C) CD38 expression for the same
cells. (D) Composite image of CD138 expression (FITC channel) with the cell nucleus (DAPI channel
of the microscope). (E) Composite image of CD38 expression (APC channel) with the cell nucleus
that was DAPI stained. Exposure times were DAPI 50 ms, FITC 500 ms, and APC 1500 ms with 20×
magnification. All images were collected using the Keyence fluorescence microscope. Shown in this
fluorescence image are cells aligned along one interleaving input channel with cross-channels on either
side of that channel.
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As a control for on-chip immunophenotyping using the microtrap device, we performed
immunophenotyping on a slide (see Figures S4 and S5) to compare with our on-chip results. RPMI-8226
cells were labeled with FITC-anti-CD138 antibodies and APC-anti-CD38 antibodies. RPMI-8226 cells
express these markers [3,46,47]. See Figures S4 and S5 for the flow cytometry results for RPMI-8226
and on-slide immunophenotyping data, respectively.
Figure 3A shows DAPI-stained cells positioned at the microtraps in the single bed device. Here,
we injected live cells followed by introduction of a fixative (2% PFA) to demonstrate the ability to fix
cells on-chip. It was evident that our device could contain live cells without damaging their integrity.
Trapped cells were stained with anti-CD138-FITC and anti-CD38-APC human antibodies (Figure 3B,C,
respectively). Figure 3D,E show the composite images of the cell nucleus (DAPI channel) with the
corresponding FITC and APC fluorescence emission signals.
Imaging of retained cells in the device for immunophenotyping was rapid. The microtrap device
could be imaged at 20× magnification for all three colors (DAPI 50 ms, FITC 500 ms and APC 1500 ms)
in <2 min. An advantage of using the microtrap device is the fact that single cells are positioned at
the micropore entrance in a 2–D format, making them easy to locate. For immunophenotyping using
the 8-bed device, >98% of cells were imaged in one plane without requiring z-stacking using a 20×
microscope objective.
3.4. Microchip Processing and Imaging of a Large Number of Single Cells
Results for isolating CTCs, CLCs, and CPCs are summarized in Table 1, and show a high number
of cells enriched from 1 mL of a patient blood sample using the sinusoidal microfluidic enrichment chip
when analyzing CPCs and CLCs due to the fact that the enrichment antibody also selects non-diseased
cells as opposed to CTCs, where the enriched fraction possesses only a few non-diseased cells. As such,
thousands of cells may be required to be analyzed via immunophenotyping or FISH [3] to identify
cancer cells (i.e., CLCs and CPCs). To facilitate the analysis of a vast number of cells, we designed the
microtrap device with eight beds capable of entrapping enriched cells, subject them to staining, and
present them in a 2-D array format for microscopic evaluation.
The 8-bed microtrap device possessed 80,000 containment pores patterned in PDMS from SU-8
reliefs. Three-level reliefs (i.e., three different heights of microstructures; see Supplementary Materials
for fabrication description) were required to reduce the pressure in the chip and achieve well-balanced
flow through the entire fluidic network (Figures 1 and 3). Because CLCs and CPCs have a diameter
ranging from 6–16 µm (see Table 1), to ensure maximum containment efficiency by the microtraps,
we used 4 × 2 µm2 cross-sections for the containment microtraps (see Figure S3A). Fluorescence
microscope images of cells contained at the microtraps and immunostained are presented in Figure 4.
Figure 4A shows a brightfield image of a single bed in the 8-bed device. Merged images of cells
aligned at micropore entrances were imaged with DAPI (50 ms acquisition time) and anti-CD38-APC
antibodies (1500 ms acquisition time) to identify CD38 on the RPMI-8226 cell surfaces; see Figure 4B.
Figure 4C shows a single bed device containing DAPI-stained cells. DAPI-stained cells in two
consecutive beds from the 8-bed device are imaged and presented in Figure 4D. As can be seen from
Figure 4C,D, the contained cells are fairly well distributed throughout the microtrap 2-D array in spite
of the decrease in the linear velocity seen down the length of the interleaving input channels (see
Figure 2B). We noticed no loss of cell integrity at the microtraps even in the region of the input/output
ends of the microtrap array where the shear stress was high (Figure 3D). Finally, when the flow was
stopped, the cells remained at their trapped location.

Materials for fabrication description) were required to reduce the pressure in the chip and achieve
well-balanced flow through the entire fluidic network (Figures 1 and 3). Because CLCs and CPCs
have a diameter ranging from 6–16 µm (see Table 1), to ensure maximum containment efficiency by
the microtraps, we used 4 × 2 µm2 cross-sections for the containment microtraps (see Figure S3A).
Fluorescence
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Cell images were processed according to the procedure listed in the materials and methods section
of this manuscript and labeled with DAPI (nuclear stain) and CD38-APC markers. (B) Brightfield
image merged with DAPI and APC channels showing the presence of the cell nucleus and CD38 on the
cell surface aligned mainly at the microtrap entrances. (C) Entrance of the single bed device imaged
using DAPI. RPMI-8226 cells were trapped inside the device at the entrance to the microtraps. (D) Two
consecutive beds of the 8-bed device imaged with the DAPI channel of the microscope for stained
RPMI-8226 cells.

3.5. On-Chip FISH
The microtrap device can be used for immunophenotyping and cytogenetic analysis, such as
FISH. FISH determines aberrations in a metaphase chromosome or chromosomes buried in interphase
nuclei from a fixed cytogenetic sample. The procedure for FISH processing on-chip is detailed in the
materials and methods section as well as the Supplementary Materials. FISH experiments were carried
out on RPMI-8226 and SUP-B15 cells with Cytocell FISH probes. The conventional workflow using
microscope slides for FISH is a tedious and time-consuming process (see Figure S6), which requires
2–3 days including overnight hybridization of FISH probes. Figure 5 shows a step-by-step workflow
for the on-chip FISH procedure, which required ~4 h of processing time and 2 µL of stock FISH probes
for the 8-bed microtrap device, producing a 5-fold reduction in FISH probe volume compared to the
slide-based FISH assay.
Figure 6A (i–iv) shows FISH signals from RPMI 8226-cells processed on-chip. FISH signals present
in both the red and green channels of the fluorescence microscope in all of the cells were seen except
for the image shown in Figure 6A (ii), where only one green signal was present due to deletion of
the target gene region. In some of the cells, only one set (1 red and 1 green) of signal was present.
One reason for losing some FISH signals is that the cells possess a 3-D structure (Figure 1E) even after
entrapment at the microtrap and the fact that a high numerical aperture (NA) microscope was used
with a short focal length; the images shown in Figure 6A were processed using only a single imaging
plane (z-axis). This issue was addressed by using z-stacking of the imaging planes over a range equal
to the average cell diameter.

experiments were carried out on RPMI-8226 and SUP-B15 cells with Cytocell FISH probes. The
conventional workflow using microscope slides for FISH is a tedious and time-consuming process
(see Figure S6), which requires 2-3 days including overnight hybridization of FISH probes. Figure 5
shows a step-by-step workflow for the on-chip FISH procedure, which required ~4 h of processing
time and 2 µL of stock FISH probes for the 8-bed microtrap device, producing a 5-fold reduction in
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FISH probe volume compared to the slide-based FISH assay.

Figure 5. Workflow of FISH using the microtrap device. The workload was reduced from 2 days
(slide method) to 4 h using the microtrap device primarily due to the hybridization time reduced from
overnight to 2 h. The probe volume required for the assay was also reduced from 10 to 2 µL as well as
using the microtrap device. Live cells were injected into the microtrap device at a flow rate of 10 µL/min
and the washing steps were done at 5 µL/min to reduce the shear stress on the fixed cells contained
within the microfluidic device.

Figure 6B shows a set of SUP-B15 cells processed using the microtrap chip for the TEL/AML1
FISH probes imaged in one image plane (i.e., no z-stacking). For TEL/AML1, probe TEL
(ETV6—Erythroblastosis Variant Gene 6 translocation, ETS) refers to a region in chromosome 12
p-arm (12p13.2), and AML1 (or RUNX1—Runt-Related Transcription Factor 1) refers to the region
in the q-arm of chromosome 21 (21q22.12). In a normal cell, there should be two red and two green
signals and in a diseased cell, two yellow fusion signals are expected due to translocation of the TEL
and AML1 genes. All of the images (Figure 6B) showed distinct red and green signals, with no clear
indication of a yellow fusion signal to identify any cell as positive for the t(12;21) translocation.
Figure 6C,D shows two examples of SUP-B15 cells processed with BCR/ABL1 FISH probes for
Ph t(9;22) (q34.12; q11.23) imaged with z-stacking (1-µm increments along the z-axis over ~15 µm).
Ph t(9;22) (q34.12; q11.23) consists of two gene regions, with one from chromosome 9 corresponding to
ABL1 gene (red labeled) and the other for the BCR (breakpoint cluster region) gene in chromosome 22
(green labeled). In a cell without a chromosomal fusion aberration, there are two green and two red
signals. If there are yellow fusion signals detected, the cell can be identified as Ph(+). Imaging of 1-µm
z-planes over a 15-µm range covered the entire cell as noted in Figure 6C,D. Those images showed
two or more signals present within the cells entrapped by the microtrap device. Figure 6C shows two
distinct red and green signals (confirmation as a cell not possessing the fusion product) and Figure 6D
shows one yellow fusion signal (second signal not visible or merged with the first one) and one red
and green signal, confirming it as a B-ALL cell that is Ph(+).
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Figure 7. (A) Immunophenotyping of cells enriched from peripheral blood of a B-ALL patient by
Figure
7. (A) Immunophenotyping of cells enriched from peripheral blood of a B-ALL patient by
targeting cells with that express the CD19 antigen. The cells were stained using DAPI (nucleus), and
targeting cells with that express the CD19 antigen. The cells were stained using DAPI (nucleus), and
monoclonal antibodies directed against TdT (FITC), CD34 (Cy3), and CD10 (Cy5). The images were
monoclonal antibodies directed against TdT (FITC), CD34 (Cy3), and CD10 (Cy5). The images were
acquired using a 40× microscope objective. The CLCs shown were DAPI(+)/CD34(+) and TdT(+),
acquired using a 40× microscope objective. The CLCs shown were DAPI(+)/CD34(+) and TdT(+), but
but CD10(−). (B) Microfluidic monitoring of a B-ALL patient from day 8 to 85 of chemotherapy.
CD10(−). (B) Microfluidic monitoring of a B-ALL patient from day 8 to 85 of chemotherapy. Total cell
Total cell count represents all DAPI(+)/CD19(+) cells selected. (C) Number of CLCs identified as
count represents all DAPI(+)/CD19(+) cells selected. (C) Number of CLCs identified as
DAPI(+)/CD19(+)/TdT(+)/CD34(±)/CD10(±). (D) Change in phenotype among CLCs for this patient
DAPI(+)/CD19(+)/TdT(+)/CD34(±)/CD10(±). (D) Change in phenotype among CLCs for this patient
for days 8 and 85.
for days 8 and 85.

We analyzed the blood of a pediatric B-ALL patient to determine MRD status during chemotherapy
We analyzed the blood of a pediatric B-ALL patient to determine MRD status during
on days 8, 15, 22, 29, 57, and 85 (Figure 7B–D). The clinical specificity was determined based on a
chemotherapy on days 8, 15, 22, 29, 57, and 85 (Figure 7B–D). The clinical specificity was determined
threshold value established from the analysis of healthy donors as negative controls (average CD19
based on a threshold value established from the analysis of healthy donors as negative controls
expressing cells was 68 cells/mL of peripheral blood). Grounded on that, we classified this patient
(average CD19 expressing cells was 68 cells/mL of peripheral blood). Grounded on that, we classified
as MRD(−) upon completion of induction and consolidation therapy on day 85. In this particular
this patient as MRD(−) upon completion of induction and consolidation therapy on day 85. In this
patient, on day 85, we observed a new phenotypic population of cells (Figure 7D) not observed during
particular patient, on day 85, we observed a new phenotypic population of cells (Figure 7D) not
the first two analyses, which were secured on days 8 and 15 during induction therapy. Cells with the
observed during the first two analyses, which were secured on days 8 and 15 during induction
CD19(+)/TdT(+)/CD34(+)/CD10(+) phenotype began to appear in the blood on day 22. Although leukemic
therapy. Cells with the CD19(+)/TdT(+)/CD34(+)/CD10(+) phenotype began to appear in the blood on
cell phenotype changes are common in B-ALL due to the effects of steroids as part of chemotherapy (i.e.,
day 22. Although leukemic cell phenotype changes are common in B-ALL due to the effects of
loss of CD34), it is likely that the aforementioned cells represent normal immature lymphoid precursors
steroids as part of chemotherapy (i.e., loss of CD34), it is likely that the aforementioned cells represent
whose morphology and immunophenotype are similar to the CLCs found in B-ALL. MRD status of this
normal immature lymphoid precursors whose morphology and immunophenotype are similar to the
patient was determined to be positive only once, which was on day 29 of treatment when the level of
CLCs found in B-ALL. MRD status of this patient was determined to be positive only once, which
enriched cells classified as CLCs (361 cells/mL) were above the threshold value.
was on day 29 of treatment when the level of enriched cells classified as CLCs (361 cells/mL) were
above the threshold value.
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4. Discussion
4. Discussion
FISH testing constitutes important and independent prognostic factors and is considered obligatory
FISH testing constitutes important and independent prognostic factors and is considered
for analyzing patient outcome [52]. Of the current ~117 human genetic tests approved by the US
obligatory for analyzing patient outcome [52]. Of the current ~117 human genetic tests approved by
Food and Drug Administration, 18 of these are FISH-based assays and most are directed toward
the US Food and Drug Administration, 18 of these are FISH-based assays and most are directed
hematological diseases, such as AML, multiple myeloma, and ALL.
toward hematological diseases, such as AML, multiple myeloma, and ALL.
AML arises from mutations occurring in progenitor cells of the myeloid lineage, which results in
AML arises from mutations occurring in progenitor cells of the myeloid lineage, which results
the inability of these cells to differentiate into functional blood cells. AML is the most common adult
in the inability of these cells to differentiate into functional blood cells. AML is the most common
leukemia, with >21,000 new cases in the US in 2018, with a 5-year survival rate of 25%. The primary
adult leukemia, with >21,000 new cases in the US in 2018, with a 5-year survival rate of 25%. The
cause of death for AML patients is due to disease relapse [53]. The WHO currently categorizes patients
primary cause of death for AML patients is due to disease relapse [53]. The WHO currently
into four groups [54]. For example, one category is patients with recurrent genetic abnormalities,
categorizes patients into four groups [54]. For example, one category is patients with recurrent genetic
which can consist of seven different chromosomal aberrations (typically balanced translocations or
abnormalities, which can consist of seven different chromosomal aberrations (typically balanced
inversions, inv). Some of these aberrations are t(8;21)(q22;q22) associated with the RUNX1/RUNX1T1
translocations or inversions, inv). Some of these aberrations are t(8;21)(q22;q22) associated with the
genes in chromosome 8, inv(16)(p13.1q22)/t(16;16)(p13.1;q22) occurring in the CBFB/MYH11 genes
RUNX1/RUNX1T1 genes in chromosome 8, inv(16)(p13.1q22)/t(16;16)(p13.1;q22) occurring in the
of chromosome 16, and inv(3)(q21q26)/t(3;3)(q21;q26) of the RPN1/EVI1 genes in chromosome 3.
CBFB/MYH11 genes of chromosome 16, and inv(3)(q21q26)/t(3;3)(q21;q26) of the RPN1/EVI1 genes in
While AML MRD is typically managed using bone marrow biopsies, we have shown that CLCs can
chromosome 3. While AML MRD is typically managed using bone marrow biopsies, we have shown
be used to determine recurrence from MRD in AML. The CLCs were enriched from blood samples
that CLCs can be used to determine recurrence from MRD in AML. The CLCs were enriched from
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using three sinusoidal microfluidic devices, with each one targeting a specific AML-associated antigen,
CD117, CD34, and CD33 [54].
Multiple myeloma is associated with the abnormal expansion of terminally differentiated B
clonal plasma cells in the bone marrow that produces an abnormal monoclonal paraprotein [55,56].
Multiple myeloma has three clinically defined stages: (i) MGUS (monoclonal gammopathy of
undetermined significance), which is the asymptomatic stage; (ii) SMM (smoldering multiple myeloma)
an intermediate phase; and (iii) the symptomatic stage referred to as active multiple myeloma [57].
In most cases, bone marrow biopsies are used to manage multiple myeloma. However, we and
others have shown that CPCs can be used to manage this disease, which used a minimally invasive
liquid biopsy [3,4,31]. In our study, we used a microfluidic device containing an array of sinusoidal
microchannels with anti-CD138 monoclonal antibodies used to enrich CPCs from multiple myeloma
patients [3]. It has been reported that in 16–50% of all multiple myeloma cases, chromosome 13q
aberrations are present [58,59]. More than 90% of reported cases show the chromosomal aberration
specifically in the 13q14 region [60]. We were able to perform FISH in the CPCs to detect the presence
of chromosome 13q deletions using a slide-based FISH method (see Figures S6 and S7).
The FISH probes used for the RPMI-8226 cells, a model of multiple myeloma, identifies the DLEU
region of chromosome 13 covering the 13q14 gene and used a red (APC channel) fluorescent probe.
The control gene, 13qter located at the end of chromosome 13, was labeled with a green fluorescent
probe (FITC channel). In a normal cell, there are two green signals and two red signals. However,
due to the polyploidy nature in some cells, there may be multiple chromosomes (>2). In CPCs, it is
expected that one or both DLEU regions (DLEU1 and DLEU2) may be deleted [61].
Figures 3 and 6 show immunophenotyping and FISH processing of RPMI-8226 cells using our
microtrap device. As expected, the data seen in Figures S4 and S5 in the Supplementary Materials
and our previous studies [3] confirmed the expression of CD138 and CD38 proteins for RPMI-8226
cells. We detected the presence of chromosome 13 as a green FISH signal corresponding to the 13qter
gene (100 kb), which was present in all images, as shown in Figure 6A. Figure 6A (i) and (ii) shows
deletion of the red signal corresponding to gene regions covering DLEU1, DLEU2, D13S319, D13S272,
and RH47934 (156 kb) as expected for the RPMI-8226 cell line, as well. Most of the RPMI-8226 cells
contained both red and green signals (Figure S7 in Supplementary Materials) lacking deletion, which
is consistent with the karyotype data for this cell line.
B-ALL is the most common cancer diagnosed in children, representing ~30% of cancer diagnoses [62].
Despite significant improvements in the overall survival of children with B-ALL, there is a group
of patients that experience relapse and ultimately die from their disease [63]. In fact, the likelihood
of relapse is 80% for patients who have MRD at the end of induction therapy, indicative of active
disease [64]. Monitoring of MRD, therefore, is considered a powerful predictor of outcome in B-ALL.
Cytogenetic abnormalities detected at diagnosis or generated during chemotherapy constitute
important prognostic factors [52]. In B-ALL patients, 25–30% of patients have hyperdiploidy, 25%
have t(12;21), 3–5% have t(9;22), 10% have MLL translocations, and 2% have iAMP21 chromosomal
abnormalities. Once an aberration is detected, it can aid in the determination of the treatment
regimen [65,66]. As another example, the detection of specific chromosome aberrations, such as
t(9;22)(q34;q11.2) for BCR-ABL1, which results in the formation of the Philadelphia (Ph) chromosome,
or t(12;21) aberrations of TEL/AML1 gene translocations are used to assign B-ALL patients to specific
targeted therapies [67].
For the SUP-B15 cell line, which is a model for B-ALL [68], there are a few targeted gene variations
that are typically evaluated using FISH [50,69,70]. MLL break-apart probes are used to detect the
breakage of the MLL gene, which is frequently found in infant B-ALL [71–73]. BCR/ABL1 probes are
used to detect the formation of the Philadelphia (Ph) chromosome produced by the fusion of two
genes from chromosome 9 and 22, which is one the most important prognostic indicators for several
hematological disorders, including B-ALL (see Figures S7, S8, and S9 for on-slide FISH analysis for
some of these chromosomal abnormalities) [74–76].

Cells 2020, 9, 519

18 of 25

In this study, the SUP-B15 cells were tested for TEL/AML1 translocations and BCR/ABL1 (Ph
chromosome) using the microtrap device for FISH. For the SUP-B15 cell line, it is expected to see two
distinct red and two green signals with the TEL/AML1 FISH probes. The TEL (ETV6) gene region
marked in red corresponds to the 12p13.2 in chromosome 12 covering 168 kb of D12S1898 region and
the green marker covers AML1 (RUNX1) in chromosome 21q22.12, a 167 kb gene region, including the
CLIC6 gene [50]. On-chip FISH results (Figure 6B) showed distinct red and green signals corresponding
to the presence of chromosome 12 and 21. Lack of a yellow signal confirmed t(12;21)(p13.2;q22.12)
translocations were not present in the SUP-B15 cell line, which agrees with the karyotype as noted in the
literature. The Philadelphia chromosome results from translocations of the ABL1 gene (9q34.11-q34.12,
red) in chromosome 9 and the BCR gene (22q11.22-q11.23, green) in chromosome 22. The BCR probe
region covers the GNAZ and RAB36 genes in a 169 kb region plus 148 kb region in telemetric BCR.
The ABL1 probe covers a 346 kb region in the middle of the FUBP3 gene. As for the karyotype data
of SUP-B15, we expected to see >90% of cells possessing the Ph chromosome (yellow fusion signal
present). No yellow signal would be considered a cell with no Ph chromosome.
Figure 6C showed that SUP-B15 cells processed on-chip with BCR/ABL1 genes expressed two
distinct red and green signals. This confirmed that there was no Ph chromosome present while in
Figure 6D it showed the presence of one yellow fusion signal, confirming Ph(+) in that cell. In Figure 6D,
we did not identify the fusion signal in this cell. However, the patient sample processed for FISH
on-chip showed improved FISH signals as seen in Figure 8.
The microtrap FISH assay resulted in an SNR of 59 for the green signal, and 68 for the red signal.
In the case of the slide-based assays, the SNR for the green and red signals were 64 and 63, respectively
(see Figure S9), indicating that the ability to detect single molecules associated with the fluorescent
reporter attached to each FISH probe was clearly visible using the microtrap device. The challenge is
that in the FISH experiments, we used a high numerical objective with a small focal distance and as
seen in Figure 1E, z-stacking was necessary to cover the genetic material housed within the nucleus.
This may have been the reason that some signals were missed. This can be obviated by using a high
numerical objective with a larger focal distance to better cover the entire nuclear region when the cells
are located at the pore entrance.
Most FISH-based assays are predicated on the use of bone marrow, which is enriched in diseased
cells compared to blood. For example, in the case of multiple myeloma, CPCs in peripheral blood
are reported to be >100-fold lower than in bone marrow [77,78]. If disease relapse and chromosomal
defects could be detected from peripheral blood, painful bone marrow biopsies could be avoided, and
physicians could obtain information in near real time and potentially implement changes in treatment
to affect better outcomes for patients with hematological diseases.
To obviate the need for a bone marrow biopsy, we used a liquid biopsy secured from a B-ALL
patient using an affinity microfluidic chip and performed immunophenotyping and FISH on those
enriched cells using our microtrap device. Similar to our previous work on the isolation of leukemic
cells from blood of patients diagnosed with AML, a sinusoidal microfluidic chip with positive affinity
selection was used [3,4], but in this case the affinity selection used a different antibody (anti-CD19
monoclonal antibodies) to enrich B-cells. While the enrichment of the CLCs and CPCs in our previous
work was accomplished using a microfluidic chip, the downstream analysis was done off-chip,
including immunophenotyping and FISH. Standard FISH workflow demands highly trained and
experienced personnel (see Figure S6), making it difficult to implement in clinical laboratories not
possessing the specialized facilities and trained personnel. Additionally, blood cells collected from a
bone marrow biopsy are used for cytogenetic analysis, requiring an invasive procedure [64].
Using our microfluidic assay, a blood sample was subjected to affinity enrichment with high
efficiency in terms of recovery and purity, and thus, the entire leukocyte population of peripheral
blood did not require cytogenetic interrogation. The only cell population interrogated was those that
expressed the target antigen, which in the case of B-ALL was CD19-expressing cells. Additionally,
enriched cells were distributed in an array-like format as determined by the position of the microtraps
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of the microtrap device (see Figure 4C,D), which made them easier to image as opposed to stochastically
distributed on a properly functionalized surface to induce cell adhesion to the surface. In addition,
the 8-bed version of the microtrap device possessed 80,000 pores for retaining cells. While the data
displayed in Table 1 show the total number of cells affinity selected (aberrant and non-aberrant) were
5314 for AML, 2840 for ALL, and 7775 for multiple myeloma, these numbers were based on a per mL
sample volume. In some cases, it may be necessary to use larger input volumes, such as 10 mL, to
search for rare CLCs and CPCs to find cells in the correct phase to elicit proper FISH signals. In these
cases, the full advantage of the large dynamic range of the 8-bed device can be realized.
To reduce the workflow for FISH, microfluidics has been suggested by several groups, with the
processing time reduced from several days using conventional slide-based FISH to several hours
using FISH-on-chip platforms [14,26–28]. In addition, microfluidics has also resulted in a reduction
in the use of expensive FISH probes. However, the reported platforms (see Table S1) required the
use of special surface coatings to allow for cells to adhere to the surface of the device. Because of the
stochastic nature of the attachment to the surface of the chip, this can create cell aggregates that made
it difficult to image single cells under high magnification to determine the chromosomal status of
the cells. Our device obviated the need of surface coatings and ordered the cells in a 2-D format to
reduce device preparation steps and simplify single cell imaging, respectively. The microfluidic was
comprised of an array of microtraps that were easily formed via a replication step in PDMS from a
relief prepared by lithography. The relief also possessed the fluidic network.
We showed in this work that the microtrap device could be coupled to a rare cell enrichment
chip to allow processing of circulating cells, such as CPCs or CLCs, with the ability to perform
immunophenotyping and FISH of the enriched cells directly from blood samples. Moreover,
experiments showed that our microtrap device was capable of containing live cells with >90%
efficiency with sufficient traps to process CLCs and CPCs enriched from blood. The microtrap device
was operated at a 10 µL/min volume flow rate to facilitate proper filling of the device without air
bubbles. At this flow rate, even though cells experienced ~570 dynes/cm2 shear stress, no obvious cell
damage was observed for cells contained by the microtraps. Cell physical survival was attributed to
the cell membrane’s ability to handle relatively high shear stress for a brief time.
Using our 8-bed device with 80,000 microtraps, we could process thousands of cells for molecular
profiling following enrichment. FISH results were achieved in <4 h by reducing the hybridization
time from overnight to 2 h. Also, automated imaging was demonstrated for phenotyping in 2 min
and FISH imaging in < 5 min, reducing the workflow for FISH compared to conventional slide-based
assays, which requires 2–3 days of processing time, most of which is done manually. The FISH-on-chip
provides full process automation.
When the cells were physically retained at the microtraps, they did possess a 3-D structure, requiring
z-stacking to cover all of the FISH probes present inside the cell nucleus. Unlike immunophenotyping,
where it was possible to use a single focusing plane because a lower magnification and associated
longer focal length was required, FISH required the use of a high numerical aperture objective with a
smaller focal length to capture high resolution images along several focal planes to image all of the
FISH probes present in the cell nucleus. Even though z-stacking was necessary for FISH imaging,
it was possible to automate this process. We set a common upper and lower threshold point in the
device and selected the points where the cells were present at the arrayed microtraps and proceeded
with automated imaging with pre-set exposure times for different filters (DAPI 200 ms, FITC 1500 ms,
Cy3/Cy5 2500 ms). Processing of the captured images using BZ-X Analyzer and FIJI is detailed in the
Supplementary Materials.
As opposed to our previous version of this device, which possessed larger microtraps [31], this
device was designed to accommodate smaller CLCs and CPCs and the higher number of cells to
analyze (see Table 1). For example, the CLCs (i.e., B-ALL cells) are smaller than CTCs and, as such,
required the use of a smaller containment pore (4 × 2 µm2 compared to 8 × 6 µm2 in our previous
report) [31]. Because the affinity selection process for CLCs and CPCs results in the enrichment of a
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much larger number of cells due to the fact that the even non-diseased cells express the capture antigen,
a larger number of containment pores were required (80,000 herein compared to 5000 in our previous
device) [31]. In addition, our previous report only performed immunophenotyping and did not carry
out FISH on the chip, as was demonstrated here.
In the current rendition, the microtrap device was made from PDMS by casting it against a
relief. However, the same device architecture can be made from a thermoplastic, such as cyclic olefin
copolymer (COC), which has some decisive advantages compared to PDMS [79]. For example, because
COC is a thermoplastic, it can be injection molded to allow production of devices at high rates and
at significantly lower chip cost compared to PDMS [79]. In fact, the entire device can be injection
molded in a single cycle, with the only requirement being cover plate bonding as a finishing step.
Also, COC has excellent optical properties that allow for high sensitivity imaging using the spectral
range typically employed for FISH [27]. COC can be UV/O3 activated to change its wettability to allow
efficient filling with aqueous solutions without creating air bubbles and does not show the typical
rapid hydrophobic recovery as seen with PDMS [80]. This will allow for the generation of a low-cost
disposable appropriate for in vitro diagnostics. When the microtrap device is physically integrated
to the cell enrichment device via a fluidic motherboard, fully automated processing of liquid biopsy
samples can be envisioned to enable clinical use.
5. Conclusions
The ability of our microtrap device was demonstrated using CPCs and CLCs for immunophenotyping
and FISH analyses of relatively small cells (Davg ~12 µm) and in high numbers. The same device could
be used to identify expression patterns of proteins and detect targeted chromosomal aberrations in
single cells. Using the 8-bed device with 80,000 containment microtraps, we could process thousands
of live or fixed cells enriched using a cell isolation microchip. FISH results were achieved in <4 h by
primarily reducing the hybridization time from overnight to 2 h, and lowering the volume of the FISH
probes required for analysis. The microtrap device was used for automated imaging for phenotypic
identification of cells in 2 min and for FISH in <5 min for all fluorescence channels without the need to
scan a relatively large area. Moreover, we were able to enrich B-cells from an ALL patient and process
those cells to identify chromosomal aberrations. In future work, the use of a thermoplastic, such as
COC, instead of PDMS will be undertaken to produce a low-cost, disposable device appropriate for
use in clinical applications.
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